Stronger Together Psoriatic Arthritis Wellness Study
NCT05652608 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2024-09-26
Summary
Patients diagnosed with psoriatic arthritis (PsA) confront decisions about how to treat their disease, interact with their health care providers, and modify lifestyle choices that may improve treatment outcomes. With sponsorship support from Janssen and in partnership with the Cleveland Clinic, this survey study will seek to understand and examine whether people living with PsA are interested in and motivated to participate in wellness activities. This cross-sectional observational survey study will help researchers and clinicians to better understand what some of the barriers and facilitators experienced by patients are when considering participation in guided online wellness activities.
People that qualify for the study and complete a 10-minute survey will be invited to participate in Immune Strength, an online wellness program developed by the Cleveland Clinic. Immune Strength is a free 10-week program for creating better habits for a more resilient immune system. By following this program, participants will have the opportunity to learn about how to develop strategies and implement behavior changes for healthier immune functioning.
Participants will be recruited by the Global Healthy Living Foundation (GHLF). GHLF is the parent organization of the CreakyJoints® (CJ) arthritis patient community and primary site for the PCORI-funded Arthritis Patient Partnership with Comparative Effectiveness Researchers (AR-PoWER) Patient Powered Research Network (PPRN), known as ArthritisPower®. ArthritisPower is a subset of CreakyJoints members who have expressed interest in participating in research and signed an informed consent form to participate in the PPRN and its associated research. Any individuals recruited from CreakyJoints or Facebook, who are not already members of ArthritisPower will be encouraged to join the ArthritisPower registry research app, but will not be required to do so in order to participate in the study.
Conditions
Interventions
- BEHAVIORAL
-
Immune Strength
Multi-week wellness program provided by the Cleveland Clinic
Sponsors & Collaborators
-
The Cleveland Clinic
collaborator OTHER -
Global Healthy Living Foundation
lead OTHER
Eligibility
- Min Age
- 19 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-03-01
- Primary Completion
- 2026-03-01
- Completion
- 2026-03-01
Countries
- United States
Study Locations
More Related Trials
-
TIght COntrol of Psoriatic Arthritis
NCT01106079 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
NCT01925768 ·Status: COMPLETED ·Phase: PHASE3
-
Understanding Participation Habits Among Plaque Psoriasis Patients
NCT06338358 ·Status: NOT_YET_RECRUITING
-
Elucidating Shared Mechanisms Contributing to NAFLD and PsA Disease Severity With Guselkumab Therapy
NCT06586281 ·Status: RECRUITING ·Phase: NA
-
Personal Precise Treatment on Psoriasis and Psoriatic Arthritis
NCT04915105 ·Status: UNKNOWN ·Phase: NA
-
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
NCT06588296 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Characterize Profile of Participant With Psoriatic Arthritis Depending on Whether Their Disease is Managed by a Dermatologist or by a Rheumatologist, and Starting Ustekinumab
NCT03336281 ·Status: COMPLETED
-
Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)
NCT01392326 ·Status: COMPLETED ·Phase: PHASE3
-
Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic Arthritis in Patients With Psoriasis Severe or Moderate With Adalimumab Treatment
NCT01316224 ·Status: COMPLETED
-
Safety and Efficacy of Secukinumab in Mild Psoriasis
NCT03131570 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis
NCT00809614 ·Status: COMPLETED ·Phase: PHASE2
-
Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome
NCT03440736 ·Status: COMPLETED ·Phase: PHASE4
-
Psorcast Mobile Study
NCT05621369 ·Status: RECRUITING
-
A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis
NCT05223868 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Guselkumab in Participants With Psoriatic Arthritis (PsA) in a Real-World Setting
NCT07220824 ·Status: RECRUITING
-
A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis
NCT05975268 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess the Change in Disease State in Adult Participants Being Treated With Oral Upadacitinib Tablets in Participants With Oligo- or Poly-artIcular Psoriatic Arthritis
NCT04758117 ·Status: COMPLETED
-
Cytokine Expression in Psoriasis Patients With and Without Joint Involvement
NCT05307809 ·Status: RECRUITING ·Phase: NA
-
A Study of Guselkumab in Participants With Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Alpha (Anti-TNF Alpha) Therapy
NCT03796858 ·Status: COMPLETED ·Phase: PHASE3
-
24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis
NCT01989468 ·Status: COMPLETED ·Phase: PHASE3
-
Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis
NCT01154101 ·Status: COMPLETED ·Phase: PHASE2
-
Analysis Of The Influence Of Metabolic Syndrome On Treatment Efficacy With Anti-Tnf In Moderate-Severe Psoriasis In Real Clinical Practice.
NCT01753245 ·Status: UNKNOWN
-
Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis
NCT04209205 ·Status: COMPLETED ·Phase: PHASE3
-
Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic Disease
NCT07280702 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Effect of Guselkumab on Cardiovascular Risk Surrogate Markers in Participants With Moderate to Severe Plaque Psoriasis
NCT05125679 ·Status: TERMINATED ·Phase: PHASE4